

B21: “What key regulatory mechanisms control the release of extracellular DNA (eDNA) from *Staphylococcus aureus* during autolysis, which significantly contributes to the structural integrity of biofilm?”

Graham S Goh, Armita A Abedi, Leibnitz J Martinez, Gowrishankar Muthukrishnan, Imre Sallai, Daniel R Schlatterer, Edward M Schwarz & Chao Xie

RESPONSE/RECOMMENDATION: Extracellular DNA (eDNA) contributes to the structure, growth and immune-evasive properties of *S. aureus* biofilms in orthopaedic infections, and is derived from both the bacteria that undergo autolysis and neutrophils that undergo NETosis at the infection site. eDNA release via autolysis is mediated by murein hydrolase, which is encoded by the *atl* gene. The *cidABC* and *lrgAB* operons modulate murein hydrolase activity and autolysis, while the *CidR* and *lytSR* transcription regulators control the expression of these operons, respectively. Other murein hydrolase-independent mechanisms of eDNA release have also been reported, such as the *gdpP*-encoded phosphodiesterase and *nuc*-encoded thermonuclease pathways.

LEVEL OF EVIDENCE: Strong

DELEGATE VOTE: Agree: [% vote], Disagree: [%], Abstain: [%]

RATIONALE: A comprehensive literature search was conducted using the terms “biofilm”, “*Staphylococcus aureus*” and “extracellular DNA” within PubMed and Scopus, which initially yielded 374 potentially relevant unique studies. These were screened by two independent reviewers, of which 146 were selected for full-text review and 37 were finally included for evaluation. *Staphylococcus aureus* is a highly prevalent cause of musculoskeletal infections [1]. Importantly, *S. aureus* is known to form biofilms, which consists of cells embedded in an extracellular matrix comprising proteins, polysaccharides, lipids, and extracellular DNA (eDNA). The exact composition of this matrix is highly strain-, time- and condition-dependent [2–4]. Although research has focused on the protein and polysaccharide constituents of the matrix [5,6], it has been increasingly recognized that eDNA contributes to the structure, stability, growth and immune-evasive properties of *S. aureus* biofilms [7]. Given the critical role of eDNA, understanding and counteracting the mechanisms that control the release of eDNA could provide an alternative therapeutic target for bacterial eradication.

eDNA in *S. aureus* biofilms is composed of DNA released by autolysis of a subfraction of the population [8,9], and autolysis-independent pathways have not yet been demonstrated in *S. aureus* [10]. As a result, eDNA is believed to encompass all chromosomally encoded genes [10] as well as some amount of extrachromosomal plasmid DNA [9], which contrasts with findings in other bacterial species. In particular, murein hydrolase plays a key role in autolysis as by degrading the peptidoglycan cell wall [11], lysing the cell and releasing genomic DNA [8,9]. Mutations in the gene coding for murein hydrolase, *atl*, result in defective biofilm formation [12] with decreased eDNA content [13,14]. Similarly, when the biofilm of an *atl* mutant was treated with DNase I, no significant difference in biomass was found compared to that of a wild-type [4].

The *cidABC* and *lrgAB* operons regulate cell death and lysis [8]. The *cidA* gene encodes a holin membrane-associated protein that oligomerizes and forms pores in the membrane [11,15]. This allows murein hydrolase, the endolysin, to access the cell wall and facilitate lysis [16]. In contrast, the *lrgA* gene encodes an antiholin protein that prevents holins from oligomerizing, thus suppressing lysis [8,15]. These operons work in tandem to modulate murein hydrolase activity and autolysis. Expression of *cidA* and *lrgA* have been shown to be affected by local oxygen concentrations [17].

CidR, a LysR-type transcriptional regulator, controls the expression of the *cidABC* operon, and its expression may in turn be affected by glucose levels [18]. In the presence of acetic acid, a byproduct of glucose metabolism, CidR enhances the transcription of *cidA* [18,19], which is likely a pH-independent interaction. While CidA plays a significant role in cell lysis, one study has shown that CidB and CidC may also contribute to this process [16].

In the same vein, the *lrgAB* operon is controlled by the *lytSR* regulatory system [20], which encompasses two signal transduction pathways: first, it detects reductions in membrane potential and enhances the transcription of *lrgA* [19,20]; additionally, it activates *lrgAB* in response to excess glucose metabolism.

Other murein hydrolase-independent mechanisms of eDNA release have also been reported. For instance, the *gdpP* gene encodes a phosphodiesterase responsible for cleaving cyclic-di-AMP. Previous studies have demonstrated that deletions of *gdpP* increase peptidoglycan cross-linking and enhance resistance to antibiotics targeting the cell envelope, which support the theory that reduced cyclic-di-AMP levels compromise cell wall integrity and promote cell lysis [21]. Higher glucose levels have also been found to decrease cyclic-di-AMP and enhance autolysis [21]. A separate study identified a mutation in the purine biosynthesis pathway (Δ purF) that significantly decreased cyclic-di-AMP levels, biofilm formation, and eDNA levels [22]. When these mutants were supplemented with exogenous cyclic-di-AMP, eDNA production levels were comparable to those of the wild-type.

Another gene implicated is the *nuc* gene, which encodes staphylococcal thermonuclease that degrades eDNA, aiding *S. aureus* in its defense against neutrophil extracellular traps (NETs) [23] and potentially facilitating the release of a subpopulation cells from the biofilm [24]. Strains with reduced thermonuclease activity exhibit greater biofilm formation, thus there is an inverse relationship between *nuc* expression and eDNA levels in the biofilm [25,26].

The intercellular adhesion locus, *ica*, present in *S. aureus* is required for biofilm formation. Previous studies have attempted to categorize methicillin-resistant *S. aureus* (MRSA) biofilms as primarily composed of protein and eDNA (*ica*-independent), while classifying methicillin-sensitive *S. aureus* (MSSA) biofilms as polysaccharide-based (*ica*-dependent). However, this characterization does not apply universally to all strains, since most *S. aureus* isolates harbor the *ica* operon. By contrast, its expression is highly regulated and influenced by various environmental factors [27]. *Ica*-dependent biofilms have observed to contain lower levels of eDNA compared to *ica*-independent biofilms [2], although this may not apply to all *ica*-dependent strains [4]. However, whether this lower level of eDNA adversely affects structural support of biofilm remains to be seen, since both *ica*-dependent and *ica*-independent biofilms were equally susceptible to

DNase I treatment [28]. Another study analyzing 47 clinical isolates of *S. aureus* also found eDNA present in biofilms of all strains, regardless of their methicillin resistance status [2].

Subinhibitory concentrations of beta-lactam antibiotics have been shown to enhance both eDNA release and biofilm formation in certain strains of *S. aureus* [29,30]. This is intuitive as cell wall damage would lead to increased eDNA release, thus promoting biofilm formation. Furthermore, subinhibitory levels of other classes of antibiotics such as clindamycin, a protein synthesis inhibitor, may also influence eDNA release in *S. aureus* biofilms, although this effect could be strain-specific [31]. Subinhibitory ceftriaxone treatment was also found to upregulate *atl* expression, contributing to increased eDNA levels within the biofilm [32]. Conversely, some antibiotics have demonstrated the opposite effect. For instance, subinhibitory levels of nisin, which disrupts cell wall depolarization and inhibits peptidoglycan synthesis, were found to reduce eDNA content in *S. aureus* biofilms [33,34]. Similarly, subinhibitory concentrations of tunicamycin, a teichoic acid synthesis inhibitor, led to decreased eDNA release [35].

The critical role of eDNA in *S. aureus* biofilms as well as its ubiquitous nature across various strains have rendered eDNA an important target for modern therapeutics. It is evident that the mechanisms of eDNA release may be influenced by various strain and environmental factors, including but not limited to local oxygen concentration, glucose levels and culture media. More importantly, further research is needed to understand the influence of subinhibitory antibiotic levels on *S. aureus* eDNA release, given its immense clinical implications for physicians treating musculoskeletal infections.

Active research in the field of in vivo biofilm formation is also focused on host biomolecule contributions including eDNA from NETs [36]. During NETosis, DNA is released from neutrophils recruited to the infection site through a process involving bacterial activation of NADPH oxidase, which generates reactive oxygen species that lead to chromatin decondensation by enzymes that modify histones (e.g. PAD4) [37,38]. Enzymes including myeloperoxidase (MPO) and neutrophil elastase (NE) then rupture the nuclear membrane to release the chromosomal DNA from the neutrophil in NETs during "lytic NETosis", where the cell dies, or "vital NETosis", which produces NETs and anuclear cytoplasts that phagocytose bacteria. Pathogens including *S. aureus* can usurp NETs by secreting endonucleases that remodels host DNA into biofilm eDNA [39]. Thus, it is unclear how effective targeting bacterial eDNA formation can be as a treatment for orthopaedic infections if the majority of eDNA in biofilm is actually derived from NETs, as some investigators have hypothesized [40].

REFERENCES

- [1] Masters EA, Ricciardi BF, Bentley KL de M, Moriarty TF, Schwarz EM, Muthukrishnan G. Skeletal infections: microbial pathogenesis, immunity and clinical management. *Nat Rev Microbiol* 2022;20:385–400. <https://doi.org/10.1038/s41579-022-00686-0>.
- [2] Sugimoto S, Sato F, Miyakawa R, Chiba A, Onodera S, Hori S, et al. Broad impact of extracellular DNA on biofilm formation by clinically isolated Methicillin-resistant and -sensitive strains of *Staphylococcus aureus*. *Sci Rep* 2018;8:2254–2254. <https://doi.org/10.1038/s41598-018-20485-z>.

- [3] Lade H, Park JH, Chung SH, Kim IH, Kim J-M, Joo H-S, et al. Biofilm Formation by *Staphylococcus aureus* Clinical Isolates is Differentially Affected by Glucose and Sodium Chloride Supplemented Culture Media. *J Clin Med* 2019;8:1853. <https://doi.org/10.3390/jcm8111853>.
- [4] Ball AL, Augenstein ED, Wienclaw TM, Richmond BC, Freestone CA, Lewis JM, et al. Characterization of *Staphylococcus aureus* biofilms via crystal violet binding and biochemical composition assays of isolates from hospitals, raw meat, and biofilm-associated gene mutants. *Microbial Pathogenesis* 2022;167:105554. <https://doi.org/10.1016/j.micpath.2022.105554>.
- [5] Hobley L, Harkins C, MacPhee CE, Stanley-Wall NR. Giving structure to the biofilm matrix: an overview of individual strategies and emerging common themes. *FEMS Microbiol Rev* 2015;39:649–69. <https://doi.org/10.1093/femsre/fuv015>.
- [6] Moormeier DE, Bayles KW. *Staphylococcus aureus* biofilm: a complex developmental organism. *Mol Microbiol* 2017;104:365–76. <https://doi.org/10.1111/mmi.13634>.
- [7] Bowden LC, Finlinson J, Jones B, Berges BK. Beyond the double helix: the multifaceted landscape of extracellular DNA in *Staphylococcus aureus* biofilms. *Front Cell Infect Microbiol* 2024;14:1400648. <https://doi.org/10.3389/fcimb.2024.1400648>.
- [8] Mann EE, Rice KC, Boles BR, Endres JL, Ranjit D, Chandramohan L, et al. Modulation of eDNA release and degradation affects *Staphylococcus aureus* biofilm maturation. *PLoS One* 2009;4:e5822–e5822. <https://doi.org/10.1371/journal.pone.0005822>.
- [9] Svarcova V, Zdenkova K, Sulakova M, Demnerova K, Pazlarova J. Contribution to determination of extracellular DNA origin in the biofilm matrix. *Journal of Basic Microbiology* 2021;61:652–61. <https://doi.org/10.1002/jobm.202100090>.
- [10] Fischer A, Kambara K, Meyer H, Stenz L, Bonetti E-J, Girard M, et al. GdpS contributes to *Staphylococcus aureus* biofilm formation by regulation of eDNA release. *International Journal of Medical Microbiology* 2014;304:284–99. <https://doi.org/10.1016/j.ijmm.2013.10.010>.
- [11] Rice KC, Mann EE, Endres JL, Weiss EC, Cassat JE, Smeltzer MS, et al. The *cidA* murein hydrolase regulator contributes to DNA release and biofilm development in *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences* 2007;104:8113–8.
- [12] Biswas R, Voggu L, Simon UK, Hentschel P, Thumm G, Götz F. Activity of the major staphylococcal autolysin Atl. *FEMS Microbiology Letters* 2006;259:260–8.
- [13] Houston P, Rowe SE, Pozzi C, Waters EM, O’Gara JP. Essential role for the major autolysin in the fibronectin-binding protein-mediated *Staphylococcus aureus* biofilm phenotype. *Infect Immun* 2011;79:1153–65. <https://doi.org/10.1128/IAI.00364-10>.
- [14] Bose JL, Lehman MK, Fey PD, Bayles KW. Contribution of the *Staphylococcus aureus* Atl AM and GL murein hydrolase activities in cell division, autolysis, and biofilm formation. *PLoS One* 2012;7:e42244–e42244. <https://doi.org/10.1371/journal.pone.0042244>.
- [15] Ranjit DK, Endres JL, Bayles KW. *Staphylococcus aureus* CidA and LrgA proteins exhibit holin-like properties. *Journal of Bacteriology* 2011;193:2468–76.
- [16] Windham IH, Chaudhari SS, Bose JL, Thomas VC, Bayles KW. SrrAB modulates *Staphylococcus aureus* cell death through regulation of *cidABC* transcription. *Journal of Bacteriology* 2016;198:1114–22.
- [17] Moormeier DE, Endres JL, Mann EE, Sadykov MR, Horswill AR, Rice KC, et al. Use of microfluidic technology to analyze gene expression during *Staphylococcus aureus* biofilm

- formation reveals distinct physiological niches. *Appl Environ Microbiol* 2013;79:3413–24. <https://doi.org/10.1128/AEM.00395-13>.
- [18] Yang S-J, Rice KC, Brown RJ, Patton TG, Liou LE, Park YH, et al. A LysR-type regulator, CidR, is required for induction of the *Staphylococcus aureus* cidABC operon. *Journal of Bacteriology* 2005;187:5893–900.
 - [19] Patton TG, Yang S, Bayles KW. The role of proton motive force in expression of the *Staphylococcus aureus* cid and lrg operons. *Molecular Microbiology* 2006;59:1395–404.
 - [20] Sharma-Kuinkel BK, Mann EE, Ahn J-S, Kuechenmeister LJ, Dunman PM, Bayles KW. The *Staphylococcus aureus* LytSR two-component regulatory system affects biofilm formation. *Journal of Bacteriology* 2009;191:4767–75.
 - [21] DeFrancesco AS, Masloboeva N, Syed AK, DeLoughery A, Bradshaw N, Li G-W, et al. Genome-wide screen for genes involved in eDNA release during biofilm formation by *Staphylococcus aureus*. *Proceedings of the National Academy of Sciences* 2017;114:E5969–78.
 - [22] Li L, Li Y, Zhu F, Cheung AL, Wang G, Bai G, et al. New mechanistic insights into purine biosynthesis with second messenger c-di-AMP in relation to biofilm-related persistent methicillin-resistant *Staphylococcus aureus* infections. *Mbio* 2021;12:e02081-21.
 - [23] Berends ET, Horswill AR, Haste NM, Monestier M, Nizet V, von Köckritz-Blickwede M. Nuclease expression by *Staphylococcus aureus* facilitates escape from neutrophil extracellular traps. *Journal of Innate Immunity* 2010;2:576–86.
 - [24] Moormeier DE, Bose JL, Horswill AR, Bayles KW. Temporal and stochastic control of *Staphylococcus aureus* biofilm development. *mBio* 2014;5:e01341. <https://doi.org/10.1128/mBio.01341-14>.
 - [25] Kiedrowski MR, Kavanaugh JS, Malone CL, Mootz JM, Voyich JM, Smeltzer MS, et al. Nuclease modulates biofilm formation in community-associated methicillin-resistant *Staphylococcus aureus*. *PLoS One* 2011;6:e26714–e26714. <https://doi.org/10.1371/journal.pone.0026714>.
 - [26] Yu J, Jiang F, Zhang F, Hamushan M, Du J, Mao Y, et al. Thermonucleases Contribute to *Staphylococcus aureus* Biofilm Formation in Implant-Associated Infections-A Redundant and Complementary Story. *Front Microbiol* 2021;12:687888–687888. <https://doi.org/10.3389/fmicb.2021.687888>.
 - [27] Fitzpatrick F, Humphreys H, O’Gara JP. Evidence for icaADBC-independent biofilm development mechanism in methicillin-resistant *Staphylococcus aureus* clinical isolates. *Journal of Clinical Microbiology* 2005;43:1973–6.
 - [28] Avila-Novoa MG, González-Gómez J-P, Guerrero-Medina PJ, Cardona-López MA, Ibarra-Velazquez LM, Velazquez-Suarez NY, et al. *Staphylococcus aureus* and methicillin-resistant *S. aureus* (MRSA) strains isolated from dairy products: Relationship of ica-dependent/independent and components of biofilms produced in vitro. *International Dairy Journal* 2021;119:105066.
 - [29] Kaplan JB, Izano EA, Gopal P, Karwacki MT, Kim S, Bose JL, et al. Low levels of β -lactam antibiotics induce extracellular DNA release and biofilm formation in *Staphylococcus aureus*. *mBio* 2012;3:e00198. <https://doi.org/10.1128/mBio.00198-12>.
 - [30] Mlynek KD, Callahan MT, Shimkevitch AV, Farmer JT, Endres JL, Marchand M, et al. Effects of Low-Dose Amoxicillin on *Staphylococcus aureus* USA300 Biofilms. *Antimicrob Agents Chemother* 2016;60:2639–51. <https://doi.org/10.1128/AAC.02070-15>.

- [31] Schilcher K, Andreoni F, Dengler Haunreiter V, Seidl K, Hasse B, Zinkernagel AS. Modulation of *Staphylococcus aureus* biofilm matrix by subinhibitory concentrations of clindamycin. *Antimicrobial Agents and Chemotherapy* 2016;60:5957–67.
- [32] Azzam A, Shawky RM, El-Mahdy TS. Sub-inhibitory concentrations of ceftriaxone induce morphological alterations and PIA-independent biofilm formation in *Staphylococcus aureus*. *Brazilian Journal of Microbiology* 2024;55:297–308.
- [33] Andre C, de Jesus Pimentel-Filho N, de Almeida Costa PM, Vanetti MCD. Changes in the composition and architecture of staphylococcal biofilm by nisin. *Brazilian Journal of Microbiology* 2019;50:1083–90.
- [34] Zhou H, Fang J, Tian Y, Lu XY. Mechanisms of nisin resistance in Gram-positive bacteria. *Annals of Microbiology* 2013;64:413–20. <https://doi.org/10.1007/s13213-013-0679-9>.
- [35] Zhu X, Liu D, Singh AK, Drolia R, Bai X, Tenguria S, et al. Tunicamycin Mediated Inhibition of Wall Teichoic Acid Affects *Staphylococcus aureus* and *Listeria monocytogenes* Cell Morphology, Biofilm Formation and Virulence. *Front Microbiol* 2018;9:1352–1352. <https://doi.org/10.3389/fmicb.2018.01352>.
- [36] Alhede M, Alhede M, Qvortrup K, Kragh KN, Jensen PØ, Stewart PS, et al. The origin of extracellular DNA in bacterial biofilm infections in vivo. *Pathog Dis* 2020;78:ftaa018. <https://doi.org/10.1093/femspd/ftaa018>.
- [37] Liu X, Arfman T, Wichapong K, Reutelingsperger CPM, Voorberg J, Nicolaes GAF. PAD4 takes charge during neutrophil activation: Impact of PAD4 mediated NET formation on immune-mediated disease. *J Thromb Haemost* 2021;19:1607–17. <https://doi.org/10.1111/jth.15313>.
- [38] Wang H, Kim SJ, Lei Y, Wang S, Wang H, Huang H, et al. Neutrophil extracellular traps in homeostasis and disease. *Signal Transduct Target Ther* 2024;9:235–235. <https://doi.org/10.1038/s41392-024-01933-x>.
- [39] Tan C, Aziz M, Wang P. The vitals of NETs. *J Leukoc Biol* 2021;110:797–808. <https://doi.org/10.1002/JLB.3RU0620-375R>.
- [40] Monticcolo F, Palomba E, Termolino P, Chiaiese P, de Alteriis E, Mazzoleni S, et al. The Role of DNA in the Extracellular Environment: A Focus on NETs, RETs and Biofilms. *Front Plant Sci* 2020;11:589837–589837. <https://doi.org/10.3389/fpls.2020.589837>.

PubMed search:

((((biofilm* OR "Biofilms"[Mesh]) AND (*Staphylococcus aureus* OR "*Staphylococcus aureus*"[Mesh] OR Staph)) AND (extracellular DNA OR eDNA OR exDNA)) AND (((1990:3000/12/12[pdat]) AND (english[LA])) OR (randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized [tiab] OR placebo [tiab] OR drug therapy [sh] OR randomly [tiab] OR trial [tiab] OR groups [tiab])) NOT (animals [mh] NOT humans [mh])))

SCOPUS search:

(TITLE-ABS(biofilm* OR "Biofilms") AND (TITLE-ABS("*Staphylococcus aureus*") OR TITLE-ABS(Staph)) AND (TITLE-ABS("extracellular DNA") OR TITLE-ABS(eDNA) OR TITLE-ABS(exDNA))) AND (PUBYEAR > 1990 AND PUBYEAR < 3000 AND LANGUAGE(english))